profile-img
Anand Patel

@Anand_88_Patel

Asst Prof & Director Inpatient Leukemia Service @UChicagoMed. @NorthwesternU @Mumedicine @NU_IntMed @UCHemOncFellows alum. tweets=mine. RT≠endorsement. He/him

calendar_today29-03-2014 13:54:02

5,8K Tweets

4,3K Followers

1,2K Following

Anand Patel(@Anand_88_Patel) 's Twitter Profile Photo
Anand Patel
@Anand_88_Patel

1 year ago

Our experience with Inotuzumab Ozagamicin re-treatment in patients with CD22+ B-ALL is out in JCO Precision Oncology! Props to 1st author Dr Juan Alban!

Follow along for a brief tweetorial! Adam DuVall MD, MPH MedChiefs University of Chicago Hematology/Oncology UChicago Medicine

ascopubs.org/doi/abs/10.120…

Our experience with Inotuzumab Ozagamicin re-treatment in patients with CD22+ B-ALL is out in @JCOPO_ASCO! Props to 1st author Dr Juan Alban! Follow along for a brief tweetorial! #leusm @AyaOncologist @MedChiefs @UChicagoHemOnc @UChicagoMed ascopubs.org/doi/abs/10.120…
account_circle
Anand Patel(@Anand_88_Patel) 's Twitter Profile Photo
Anand Patel
@Anand_88_Patel

1 year ago

Median overall survival in adults with relapsed B-ALL is quite poor, particularly in those already treated with blinatumomab and/or InO. There is little published data about the utility of re-treatment with these drugs.

account_circle
Anand Patel(@Anand_88_Patel) 's Twitter Profile Photo
Anand Patel
@Anand_88_Patel

1 year ago

We identified 6 pts at our center that received InO for R/R B-ALL and were subsequently re-treated for relapse/progression of CD22+ disease. Characteristics are summarized in the below tables. 5 of 6 pts had a CR to the 1st treatment with InO and 1 pt had a PR.

We identified 6 pts at our center that received InO for R/R B-ALL and were subsequently re-treated for relapse/progression of CD22+ disease. Characteristics are summarized in the below tables. 5 of 6 pts had a CR to the 1st treatment with InO and 1 pt had a PR.
account_circle